scholarly journals Studies on liposome-encapsulated carboquone. IV. Enhancement of antitumor activity of carboquone against Ehrlich ascites carcinoma by encapsulation.

1982 ◽  
Vol 5 (1) ◽  
pp. 34-39
Author(s):  
MASAFUMI HISAOKA ◽  
KAZUHIRO TSUKADA ◽  
TADASHI MORIOKA ◽  
TAKAKO INOMATA ◽  
MASAO ARAKAWA
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Ehrlich Ascites

scholarly journals Antitumor potential of Citrus limetta fruit peel in Ehrlich ascites carcinoma bearing Swiss albino mice

2012 ◽  
Vol 2 (1) ◽  
pp. 10 ◽  
Author(s):  
Sriparna Kundusen ◽  
Asis Bala ◽  
Biswakanth Kar ◽  
Sanjib Bhattacharya ◽  
Upal K. Mazumder ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Cell ◽  
Life Span ◽  
Blood Cells ◽  
Tumor Volume ◽  
Ehrlich Ascites Carcinoma ◽  
Viable Tumor Cell ◽  
Fruit Peel ◽  
Ehrlich Ascites ◽  
Citrus Limetta

<em>Citrus limetta </em>Risso (Rutaceae), commonly known as sweet lime in English and <em>Mousambi</em> in India, has been traditionally used for several medicinal purposes. This study explored the relationship between <em>Citrus limetta </em>fruit peel and its antitumor activity against Ehrlich ascites carcinoma (EAC) bearing mice. The antitumor activity of methanol extract of peel of <em>Citrus limetta</em> fruits (MECL) was evaluated against EAC cell line in Swiss albino mice. Twenty-four hours after intraperitoneal inoculation of tumor EAC cells in mice, MECL was administered at 200 and 400 mg/kg body weight i.p. daily for nine consecutive days. On the 10th day, half of the mice were sacrificed for the estimation of tumor growth (tumor volume, viable and non-viable tumor cell counts), and hematologic parameters (red blood cells, white blood cells and hemoglobin). The rest were kept alive for assessment of survival parameters, <em>i.e. </em>median survival time and percentage increase in life span of EAC bearing mice. Intraperitoneal administration of MECL at the doses of 200 and 400 mg/kg for nine days to the carcinoma induced mice demonstrated a significant (P&lt;0.001) decrease in tumor volume, viable tumor cell count, tumor weight and a significant (P&lt;0.001) improvement in hematological parameters and life span as compared to the EAC control mice. The present study establishes marked and dose dependant anti-tumor effect of <em>C. limetta </em>fruit peel against Ehrlich ascites carcinoma bearing Swiss mice.

ANTITUMOR ACTIVITY OF CAPPARIS SEPIARIA ON EHRLICH ASCITES CARCINOMA IN MICE

2011 ◽  
Vol 2 (4) ◽  
Author(s):  
Y VenuGopal ◽  
Ravindranath A ◽  
Kalpana G ◽  
Prabhaker Reddy.V
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Ehrlich Ascites

scholarly journals In vitro and in vivo evaluation of antitumor activity of methanolic extract of Argyreia nervosa leaves on Ehrlich ascites carcinoma

2015 ◽  
Vol 10 (2) ◽  
pp. 399
Author(s):  
Bhawna Sharma ◽  
Isha Dhamija ◽  
Sandeep Kumar ◽  
Hema Chaudhary
Keyword(s):  
Antitumor Activity ◽  
Solid Tumor ◽  
Methanolic Extract ◽  
Ehrlich Ascites Carcinoma ◽  
Ehrlich Ascites ◽  
Wide Range ◽  
Antioxidant Parameters ◽  
Argyreia Nervosa

<p>The herb of importance like <em>Argyreia nervosa</em> has shown wide range of pharmacological activities. Its methanolic extract of <em>A. nervosa</em> has been explored against Ehrlich ascites carcinoma (EAC) induced liquid and solid tumor in mice. Liquid and solid tumors were induced by intraperitoneal and subcutaneous transplantation of EAC cells in Balb/C mice. Significant and dose dependant results are observed when the mice are sacrificed on 15<sup>th</sup> day for estimation of tumor proliferation, hematological, biochemical and hepatic antioxidant parameters. Mean survival time (days) was increased to 36.5 from 20.5 extract treated mice. The extract also showed a decrease (p&lt;0.001) in body weight and percentage reduction in tumor volume respectively when it was evaluated in solid tumor induced mice for a period of 30 days.  From the result it was concluded that the extract has as a potent antitumor activity and that is comparable to 5-fluorouracil.</p><p> </p>

Evaluation of antitumor activity of Urena lobata against Ehrlich ascites carcinoma treated mice

2018 ◽  
Vol 19 (1) ◽  
pp. 21-26 ◽  
Author(s):  
Rinku Mathappan ◽  
Kesavanarayanan Krishnan Selvarajan ◽  
Sabitha Sujeet ◽  
Sourav Tribedi
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Ehrlich Ascites

scholarly journals Evaluation of antitumor activity and antioxidant status of Alternanthera brasiliana against Ehrlich ascites carcinoma in Swiss albino mice

2015 ◽  
Vol 7 (1) ◽  
pp. 66 ◽  
Author(s):  
PavanKumar Samudrala ◽  
BibinBaby Augustine ◽  
EshvendarReddy Kasala ◽  
LakshmiNarendra Bodduluru ◽  
Chandana Barua ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Antioxidant Status ◽  
Ehrlich Ascites Carcinoma ◽  
Swiss Albino Mice ◽  
Ehrlich Ascites ◽  
Albino Mice

scholarly journals Antitumor Activity of the Carboplatin-α-Cyclodextrin Adduct

1997 ◽  
Vol 4 (6) ◽  
pp. 305-306
Author(s):  
Weiping Liu ◽  
Huizhou Xiong ◽  
Yikun Yang ◽  
Ling Li ◽  
Zhiqiang Shen ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Antitumor Efficacy ◽  
Sarcoma 180 ◽  
Murine Tumors ◽  
Ehrlich Ascites

Antitumor activity of the adduct between Carboplatin and α-cyclodextrin has been tested against Sarcoma 180 (S180) and Ehrlich ascites carcinoma (EAC) murine tumors. The preliminary toxicity has also been evaluated by histological examinations of the treated animals. The results show the adduct has less antitumor efficacy than and similar toxicity to Carboplatin.

Evaluation of Cisplatin Combined with Ondansetron in Ehrlich Ascites Carcinoma in Vitro and in Vivo

2000 ◽  
Vol 86 (2) ◽  
pp. 153-156 ◽  
Author(s):  
Osama Ahmed Badary ◽  
Sahar Moustafa Sharaby ◽  
Sanaa Abd El-Baky Kenawy ◽  
Ezz El-Deen El-Denshary ◽  
Farid Mohamed Ahmed Hamada
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Host Tissue ◽  
Nausea And Vomiting ◽  
Single Treatment ◽  
Blood Cell Count ◽  
Ehrlich Ascites ◽  
Eac Cells

Aims and background Nausea and vomiting occur in the majority of patients receiving cisplatin (CDDP) chemotherapy. Ondansetron, a new 5-HT3 receptor antagonist, has been used effectively to control CDDP-induced nausea and vomiting. This study examined the potential of ondansetron to interfere with CDDP antitumor activity and toxicity in Ehrlich ascites carcinoma (EAC). Methods The influence of ondansetron on CDDP cytotoxicity was evaluated using EAC cells in culture. In addition, the influence of ondansetron pretreatment on CDDP-induced antitumor activity and host tissue toxicity was studied in EAC-bearing mice. Results Ondansetron (0.25 μM) enhanced CDDP (0–32 μM) cytotoxicity against EAC cells in vitro. In EAC-bearing mice ondansetron (0.2 mg/kg, ip) administered 1 h before CDDP (7 mg/kg, ip) did not modify the antitumor activity of CDDP. CDDP (7 mg/kg, ip) single treatment induced significant increases in blood urea nitrogen (2-fold) and serum creatinine (2.5-fold) and significant decreases in hematocrit (25%) and white blood cell count (39%) compared to saline treatment. Mice receiving ondansetron 1 h before CDDP showed no significant enhancement of CDDP-induced nephrotoxicity or myelosuppression compared to those pretreated with saline receiving the same dose of CDDP. Conclusions This study suggests that the use of ondansetron to control CDDP-induced nausea and vomiting does not affect CDDP antitumor efficacy.

Sign in / Sign up

Export Citation Format

Share Document